Biosplice announced today that its collaboration with The Roskamp Institute has been awarded funding by the US Department of Defense. Biosplice Therapeutics Announces Department of Defense (DoD) Award to Fund Collaboration with The Roskamp Institute to Advance its Neurology Program

JERUSALEM, March 08, 2024 (GLOBE NEWSWIRE) — Entera Bio Ltd. (NASDAQ: ENTX), (“Entera” or the “Company”) a leader in the development of orally delivered peptides, today reported financial results and key business updates for the fourth quarter and year ended December 31, 2023. Entera Bio Announces Full Year 2023 Financial Results and Provides Business Updates

SAN FRANCISCO, March 08, 2024 (GLOBE NEWSWIRE) — 89bio, Inc. (the “Company” or “89bio”) (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardiometabolic diseases, today announced that the Compensation Committee of the Company’s Board of Directors approved the grant of non-qualified stock options to purchase an aggregate of 10,800 shares of the Company’s common stock to a new employee (the “Inducement Grant”) on March 6, 2024 (the “Grant Date”). The Inducement Grant has been granted pursuant to the Company’s 2023 Inducement Plan (the “Plan”). The Inducement Grant was granted as an inducement material to this individual entering into employment with 89bio in accordance with Nasdaq Listing Rule 5635(c)(4). 89bio Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

The combined treatment with the quinazoline and colistin targets Salmonella by simultaneously inhibiting its resistance mechanisms against colistin and disrupting the bacterium’s envelope electrochemical equilibrium. This synergistic interplay not only introduces a new route to counter MDR bacteria but also lays the groundwork for potentially addressing resistance challenges associated with other antibiotics. The efficacy of the dual treatment in mitigating mortality within an in vivo insect infection model marks a stride toward potential therapeutic applications. Research Article: Lobertti, C.A.; Gizzi, F.O.; Magni, C.; Rial, A.; Chabalgoity, J.A.; Yim, L.; Blancato, V.S.; Asquith, C.R.M.; García Véscovi, E. Enhancing colistin efficacy against Salmonella infections with a quinazoline-based dual therapeutic strategy. Sci Rep. 2024 Mar 1;14(1):5148. doi: 10.1038/s41598-024-55793-0.

As we age, our hematopoietic (blood-forming) stem cells (HSCs) become less able to produce new red and white blood cells and other vital blood components—contributing to chronic inflammation and accelerating the onset of blood cancers and degenerative diseases. Researchers at Albert Einstein College of Medicine and the National Cancer Institute-designated Montefiore Einstein Comprehensive Cancer Center (MECCC) have found that failing HSC function can be prevented or even reversed by reducing iron levels in these adult stem cells. The findings published March 7 in the print edition of the journal Cell Stem Cell. https://www.cell.com/cell-stem-cell/fulltext/S1934-5909(24)00041-9

A new PET radiotracer can differentiate diseased tissues from healthy tissues based on fructose metabolism, according to new research published in the March issue of The Journal of Nuclear Medicine. Fructose metabolism—or fructolysis—is indicative of a variety of diseases, and by noninvasively mapping fructolysis physicians can more accurately detect diseases and treat them earlier. With this new fructose-based imaging dye, researchers compared 4FDF to the clinical standard for glucose mapping, FDG, in a mouse model. Like FDG, 4FDF accumulated in tumor tissue, but unlike FDG, it did not accumulate in healthy brain or healthy heart, two organs with very high FDG uptake. When inflammation was induced in the brain and heart, both organs showed strong 4FDF signals. Bone uptake was minimized with 4FDF, further supporting the need for specific mapping of tissues that have undergone the glucose-to-fructose fuel switch that… 

A research team led by Tomoya Nakazawa of Hamamatsu Photonics (Japan) recently developed a novel methodology to estimate BGLs from NIR measurements. Their work, which could revolutionize noninvasive blood glucose monitoring, was published in the Journal of Biomedical Optics. The core contribution of this study is a new blood glucose level index that the research team derived from basic NIR formulas. Their approach begins with the extraction of oxyhemoglobin (HbO2) and deoxyhemoglobin (Hb) signals from NIR measurements. Through the analysis of massive amounts of data on NIR measurements, the researchers realized that the phase delay (asynchronicity) between the low-frequency and oscillating components of HbO2 and Hb signals is closely related to the degree of oxygen consumption during each cardiac cycle, thereby serving as a gauge for metabolism. “This phase delay-based metabolic index, which has not been reported by other researchers,… 

Mit der an der UC Riverside entwickelten Technologie können Wissenschaftler erstmals während einer Operation hochauflösende Bilder des menschlichen Rückenmarks erstellen. Der Fortschritt könnte dazu beitragen, Millionen von Menschen, die unter chronischen Rückenschmerzen leiden, echte Linderung zu verschaffen. Die als fUSI oder funktionelle Ultraschallbildgebung bekannte Technologie ermöglicht es Ärzten nicht nur, das Rückenmark zu sehen, sondern ermöglicht ihnen auch, die Reaktion des Rückenmarks auf verschiedene Behandlungen in Echtzeit abzubilden. Ein heute in der Fachzeitschrift Neuron veröffentlichter Artikel beschreibt detailliert, wie fUSI bei sechs Personen funktionierte, die sich zur Behandlung chronischer Rückenschmerzen einer elektrischen Stimulation unterzogen.

Alzheimer kann uns alle treffen – aber Frauen erkranken deutlich häufiger als Männer. Insgesamt sind zwei Drittel der Erkrankten Frauen, für Deutschland entspricht dies einer Zahl von etwa 800.000 Betroffenen. Forscher*innen hatten dieses Ungleichgewicht lange der höheren Lebenserwartung von Frauen zugeschrieben, da der größte Risikofaktor für die Alzheimer-Krankheit das Alter ist. Heute weiß man jedoch: Die Wahrscheinlichkeit, dass eine Frau an Alzheimer erkrankt, ist höher als bei einem Mann, unabhängig von der jeweiligen Lebenserwartung. Als Ursache rückte in den letzten Jahren verstärkt der weibliche Hormonhaushalt in den Blick. Jetzt zeigt ein neuer Übersichtsartikel aus dem Fachmagazin Neuroforum, dass Ursachen auch in den geschlechtsspezifischen Genen zu finden sind. Die Autoren Privatdozent Dr. Alex Yang Liu und Prof. Klaus Faßbender vom Universitätsklinikum des Saarlandes haben drei Faktoren identifiziert, die mutmaßlich dazu beitragen, dass Frauen häufiger an Alzheimer erkranken. Anlässlich des Weltfrauentages am…